Session » (0955–0977) Systemic Sclerosis & Related Disorders – Basic Science Poster I

Date: Monday, October 27, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 0964

A Single-Cell Atlas Reveals Dermal Endothelial Heterogeneity and Disease-Specific Pathways in Autoimmune Disorders

10:30AM-12:30PM: Abstract Number: 0958

Asynchronous Resolution of Inflammation and Fibrosis in A Prolonged Experimental Model Suggests Distinct Temporal Dynamics And Resolution Mechanisms in Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 0973

Effects of a Novel Hybrid Protein Based on S100 on Macrophage Polarization and Its Therapeutic Efficacy in a Bleomycin-Induced Systemic Sclerosis Mouse Model.

10:30AM-12:30PM: Abstract Number: 0969

FOXO1 Mediated Polysialic Acid Dysregulation in Severe Systemic Sclerosis (SSc): A Novel Biomarker and Therapeutic Target?

10:30AM-12:30PM: Abstract Number: 0970

Genomic instability in systemic sclerosis is promoted by metabolic remodelling via a FOXO1-dependent axis

10:30AM-12:30PM: Abstract Number: 0963

Increased expression of M2 pro-fibrotic markers in circulating monocytes and cultured monocyte-derived macrophages from systemic sclerosis patients with progressive interstitial lung disease (ILD)

10:30AM-12:30PM: Abstract Number: 0965

Inhibition of Nicotinamide N-Methyltransferase Reverses Fibroblast Activation via Epigenetic and Metabolic Remodeling in Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 0966

Integrated Bulk and Single Cell Analysis Confirms Differential Upregulation of the Proton Sensing Receptor GPR68 in Systemic Sclerosis Across Disease Stage and Subset

10:30AM-12:30PM: Abstract Number: 0975

Linezolid prevents fibroblast activation and ameliorates tissue fibrosis by inhibition of mitochondrial translation

10:30AM-12:30PM: Abstract Number: 0976

LMPTP Drives Fibrosis in Systemic Sclerosis via TGF-beta Signaling Activation

10:30AM-12:30PM: Abstract Number: 0959

Longitudinal Multiomic Study of Skin, Peripheral Blood, and Serum: Serum Proteome Reflects the Disease Process at the End-organ Level and Predicts the Course of Modified Rodnan Skin Score

10:30AM-12:30PM: Abstract Number: 0956

Mapping Metabolic Changes in Skin Fibrosis in Systemic Sclerosis by Spatial Proteomics

10:30AM-12:30PM: Abstract Number: 0968

Mesenchymal Stromal Cells in Systemic Sclerosis are Dysfunctional and Have a Profibrotic and Senescent Phenotype

10:30AM-12:30PM: Abstract Number: 0957

Multi-Omic Profiling Reveals a Monocyte-Vascular Signature Associated with the Regression of Skin Fibrosis in SSc

10:30AM-12:30PM: Abstract Number: 0960

Pharmaceutical Blockade of the Neonatal Fc Gamma Receptor Ameliorates Autoimmunity, Inflammation and Fibrosis in the Topoisomerase I Mouse Model of Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 0972

Prominent endothelial senescence in systemic sclerosis skin

10:30AM-12:30PM: Abstract Number: 0961

Retinoic acid-related orphan receptor-α: A novel upstream regulator of Hippo signaling and potential therapeutic target in fibrosis

10:30AM-12:30PM: Abstract Number: 0967

Single-Cell RNA Sequencing Reveals a Prominent Pro-Inflammatory Gene Signature of Dermal Fibroblasts in Pre-Stages of SSc

10:30AM-12:30PM: Abstract Number: 0962

Spatial Proteomics Analysis of the organization of tertiary lymphoid structures in Systemic Sclerosis Skin

10:30AM-12:30PM: Abstract Number: 0955

Surveying RNA methylation in scleroderma highlights roles for demethylases ALKBH5 and FTO in fibrosis

10:30AM-12:30PM: Abstract Number: 0977

The nuclear receptor DAX1 regulates WNT/β-catenin signaling to promote fibroblast activation and skin fibrosis in systemic sclerosis

10:30AM-12:30PM: Abstract Number: 0974

Tissue resident macrophages derived from induced pluripotent stem cells induce tissue fibrosis in human skin equivalent models of systemic sclerosis

10:30AM-12:30PM: Abstract Number: 0971

Unraveling the role of the hippo pathway in systemic sclerosis: A focus on TEADs and VGLL3

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].